Table 1.
Cladosporin Activity against Plasmodium Blood and Liver Stages and Human Cell Lines
| Strain or Cell Line |
Plasmodium Activity |
Cell Line |
|---|---|---|
| IC50 (nM) | CC50 (nM) | |
| 3D7a | 45.4 ± 6.0 | |
| Camp Ra | 77.9 ± 3.2 | |
| D10a | 89.6 ± 11.4 | |
| D6a | 72.1 ± 3.1 | |
| K1a | 80.1 ± 10.3 | |
| NF54a | 87.9 ± 5.3 | |
| FCBa | 66.7 ± 4.9 | |
| FCR3a | 57.4 ± 10.8 | |
| HEp2b | 9,666 ± 2,200 | |
| HeLab | 74,285 ± 18,830 | |
| HepG2b | 43,568 ± 25,080 | |
| Huh7b | >100,000 | |
| HepG2-CD81b | >10,000 | |
| P. yoelii liver schizontc | 39.1 ± 18.4 | |
| Dd2 clone1 | 62.5 ± 3.5 | |
| Cladosporin-RDd2 clone#1a | 377.1 ± 31.4 | |
| Cladosporin-RDd2 clone#2a | 389.5 ± 39.6 | |
| Cladosporin-RDd2 clone#3a | 374.7 ± 54.0 |
a
IC50 determined by the 72 hr SYBR Green cell proliferation assay.
b
Fifty percent cytotoxic inhibitory concentration (CC50) was determined by CellTiter-Glo viability assay.
c
IC50 based on the mean parasite area calculated in the high-content screen.